travoprost Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	2716	157283-68-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: izba travoprost travaprost travatan travatanz	A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Molecular weight: 500.56 Formula: C26H35F3O6 CLOGP: 3.92 LIPINSKI: 1 HAC: 6 HDO: 3 TPSA: 96.22 ALOGS: -4.82 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

izba
travoprost
travaprost
travatan
travatanz

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Molecular weight: 500.56
Formula: C26H35F3O6
CLOGP: 3.92
LIPINSKI: 1
HAC: 6
HDO: 3
TPSA: 96.22
ALOGS: -4.82
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 27, 2001	EMA
March 16, 2001	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	585.01	15.49	295	7748	92792	46585227
Intraocular pressure increased	391.95	15.49	107	7936	5850	46672169
Ocular hyperaemia	294.26	15.49	115	7928	19595	46658424
Eye irritation	291.30	15.49	109	7934	16505	46661514
Glaucoma	196.35	15.49	81	7962	15840	46662179
Eye pain	152.84	15.49	81	7962	27859	46650160
Product delivery mechanism issue	116.29	15.49	23	8020	291	46677728
Product packaging quantity issue	96.31	15.49	25	8018	1119	46676900
Eye pruritus	96.17	15.49	45	7998	11853	46666166
Visual acuity reduced	72.51	15.49	46	7997	22067	46655952
Foreign body sensation in eyes	62.85	15.49	20	8023	1856	46676163
Visual impairment	62.82	15.49	67	7976	66622	46611397
Eye allergy	51.54	15.49	13	8030	518	46677501
Dry eye	48.78	15.49	41	8002	30281	46647738
Vision blurred	48.40	15.49	64	7979	79644	46598375
Ocular discomfort	46.24	15.49	18	8025	3017	46675002
Intraocular pressure decreased	45.13	15.49	9	8034	119	46677900
Product quality issue	44.97	15.49	42	8001	35606	46642413
Product container issue	43.52	15.49	15	8028	1784	46676235
Product container seal issue	40.46	15.49	8	8035	101	46677918
Eye disorder	36.56	15.49	28	8015	18113	46659906
Liquid product physical issue	35.83	15.49	10	8033	590	46677429
Retinal disorder	34.63	15.49	12	8031	1449	46676570
Eye inflammation	32.61	15.49	15	8028	3794	46674225
Hypersensitivity	31.88	15.49	76	7967	150245	46527774
Normal tension glaucoma	31.02	15.49	6	8037	67	46677952
Growth of eyelashes	30.97	15.49	7	8036	173	46677846
Hypoacusis	30.96	15.49	27	8016	20942	46657077
Lacrimation increased	28.75	15.49	23	8020	15838	46662181
Subacute cutaneous lupus erythematosus	27.91	15.49	11	8032	1904	46676115
Conjunctival hyperaemia	27.51	15.49	11	8032	1978	46676041
Accidental exposure to product	26.89	15.49	25	8018	21056	46656963
Cataract	26.82	15.49	36	8007	45379	46632640
Eye swelling	25.95	15.49	24	8019	20079	46657940
Corneal disorder	25.59	15.49	10	8033	1693	46676326
Blepharal pigmentation	25.15	15.49	5	8038	65	46677954
Blindness	25.02	15.49	22	8021	17247	46660772
Hypertrophic cardiomyopathy	24.58	15.49	9	8034	1275	46676744
Photophobia	24.07	15.49	20	8023	14524	46663495
Optic nerve injury	24.04	15.49	7	8036	481	46677538
Open angle glaucoma	22.84	15.49	6	8037	281	46677738
Punctate keratitis	22.58	15.49	7	8036	596	46677423
Gastrointestinal bacterial infection	21.76	15.49	7	8036	672	46677347
Eye haemorrhage	21.45	15.49	14	8029	7038	46670981
Eyelid irritation	21.21	15.49	6	8037	372	46677647
Macular degeneration	21.17	15.49	14	8029	7191	46670828
Eyelid oedema	20.89	15.49	16	8027	10341	46667678
Intraocular pressure test abnormal	20.88	15.49	5	8038	160	46677859
Visual field defect	20.79	15.49	13	8030	6070	46671949
Rheumatoid arthritis	20.31	15.49	8	8035	240207	46437812
Gastroenteritis salmonella	20.23	15.49	6	8037	440	46677579
Myoglobin blood increased	20.06	15.49	8	8035	1428	46676591
Dark circles under eyes	19.95	15.49	6	8037	461	46677558
Expired product administered	19.18	15.49	12	8031	5610	46672409
Eye discharge	18.03	15.49	11	8032	4917	46673102
Corneal opacity	17.47	15.49	6	8037	706	46677313
Corneal epithelium defect	17.17	15.49	5	8038	344	46677675
Keratic precipitates	17.08	15.49	4	8039	116	46677903
Trabeculectomy	16.64	15.49	3	8040	22	46677997
Stag horn calculus	16.22	15.49	4	8039	145	46677874
Choroidal effusion	16.09	15.49	5	8038	429	46677590
Starvation	15.63	15.49	4	8039	169	46677850
Product packaging issue	15.50	15.49	6	8037	990	46677029

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	521.83	17.33	199	4619	34480	29913180
Intraocular pressure increased	229.00	17.33	67	4751	5053	29942607
Eye irritation	221.95	17.33	67	4751	5629	29942031
Ocular hyperaemia	176.26	17.33	63	4755	8980	29938680
Eye pain	93.29	17.33	43	4775	11746	29935914
Product delivery mechanism issue	83.34	17.33	15	4803	118	29947542
Glaucoma	71.16	17.33	29	4789	5879	29941781
Eye pruritus	67.65	17.33	25	4793	3902	29943758
Visual acuity reduced	61.99	17.33	36	4782	15810	29931850
Growth of eyelashes	58.20	17.33	10	4808	58	29947602
Blepharitis	48.59	17.33	14	4804	995	29946665
Cystoid macular oedema	44.41	17.33	12	4806	673	29946987
Expired product administered	37.70	17.33	15	4803	2854	29944806
Visual impairment	34.95	17.33	33	4785	30405	29917255
Foreign body sensation in eyes	32.71	17.33	9	4809	540	29947120
Erythema of eyelid	31.49	17.33	9	4809	621	29947039
Conjunctivitis	30.80	17.33	18	4800	7982	29939678
Eye inflammation	30.33	17.33	11	4807	1626	29946034
Vision blurred	29.54	17.33	35	4783	41781	29905879
Blindness	28.27	17.33	20	4798	12289	29935371
Lacrimation increased	27.58	17.33	16	4802	7000	29940660
Product packaging quantity issue	26.27	17.33	8	4810	688	29946972
Dry eye	26.09	17.33	15	4803	6453	29941207
Open angle glaucoma	24.37	17.33	6	4812	232	29947428
Ocular surface disease	24.24	17.33	5	4813	85	29947575
Conjunctivitis allergic	23.90	17.33	7	4811	527	29947133
Retinal detachment	23.85	17.33	13	4805	5047	29942613
Blindness unilateral	23.85	17.33	12	4806	3960	29943700
Eye discharge	22.66	17.33	9	4809	1704	29945956
Cataract	21.91	17.33	22	4796	21813	29925847
Product container issue	20.86	17.33	7	4811	823	29946837
Cerebellar stroke	20.14	17.33	5	4813	200	29947460
Vitreous floaters	20.06	17.33	10	4808	3234	29944426
Electrolyte depletion	19.84	17.33	5	4813	213	29947447
Product quality issue	18.99	17.33	19	4799	18755	29928905
Liquid product physical issue	18.51	17.33	5	4813	280	29947380
Hepatitis fulminant	18.23	17.33	10	4808	3931	29943729
Corneal oedema	17.73	17.33	7	4811	1305	29946355
Intraocular pressure decreased	17.42	17.33	4	4814	114	29947546

Pharmacologic Action:

Source	Code	Description
ATC	S01EE04	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA CS	M0017805	Prostaglandins
FDA EPC	N0000175454	Prostaglandin Analog
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35674	antihypertensive
CHEBI has role	CHEBI:39456	antiglaucoma agent
CHEBI has role	CHEBI:50266	prodrugs
CHEBI has role	CHEBI:66900	prostaglandin receptor agonists
CHEBI has role	CHEBI:66981	ophthalmologicals

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067
Iritis	contraindication	65074000	DOID:1406
Uveitis	contraindication	128473001	DOID:13141
Cystoid macular edema	contraindication	193387007	DOID:4447

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST	Ki	7.28		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Prostaglandin E2 receptor EP3 subtype	GPCR	P43115	PE2R3_HUMAN		Ki	5.46		SCIENTIFIC LITERATURE

External reference:

ID	Source
4021261	VUID
N0000148702	NUI
D01964	KEGG_DRUG
4021261	VANDF
C3832613	UMLSCUI
CHEBI:746859	CHEBI
CHEMBL1200799	ChEMBL_ID
D000069557	MESH_DESCRIPTOR_UI
7775	INN_ID
DB00287	DRUGBANK_ID
WJ68R08KX9	UNII
5282226	PUBCHEM_CID
7102	IUPHAR_LIGAND_ID
1539201	RXNORM
15936	MMSL
200905	MMSL
41255	MMSL
d04753	MMSL
009114	NDDF
129493000	SNOMEDCT_US
391664000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0260	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA	22 sections
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0946	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA	25 sections
Travoprost Ophthalmic Solution, 0.004%	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9651	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6185	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections
Travoprost Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	42571-130	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5968	SOLUTION	0.04 mg	OPHTHALMIC	NDA	22 sections
Travoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0593	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution USP, 0.004%Travoprost	Human Prescription Drug Label	1	62332-510	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections